Dollar figures in thousands, except per share; parentheses denote losses.
CombiMatrix
Bioinformatics
Dec. 31
%
4th QTR
2007
2006
CHG
Profit
($3,458)
($4,503)
+23.2
Per share
(0.58)
Revenues
1,875
859
+118
ANNUAL
2007
2006
CHG
Profit
($12,553)
($19,961)
+37.1
Per share
(2.10)
Revenues
6,029
5,740
+5.0
COMMENT: The Mukilteo company, a recent spinoff of Acacia Research, saw its losses narrow on higher quarterly revenue due to Department of Defense contracts and sales of diagnostic services.
Flow International
Ultrahigh-pressure water-jet tools
Jan. 31
%
3rd QTR
2008
2007
CHG
Profit
$5,897
$2,029
+191
Per share
0.16
0.05
+220
Sales
66,271
56,038
+18.3
9 MOS
2008
2007
CHG
Profit
$8,569
$6,813
+25.8
Per share
0.23
0.18
+27.8
Sales
184,111
163,851
+12.4
COMMENT: The Kent company held the line on operating expenses in the fiscal third quarter, allowing more sales growth to flow to the bottom line. European and South American sales rose 34 percent; sales in North America, Flow’s biggest market, grew 18 percent. Last month, the Federal Trade Commission asked Flow for more information related to its proposed purchase of Omax, a similar company also in Kent. Flow said it’s cooperating and still expects the deal to go through.
Microvision
Miniature imaging systems
Dec. 31
%
4th QTR
2007
2006
CHG
Profit
($6,022)
($8,681)
+30.6
Per share
(0.11)
(0.21)
+47.6
Sales
2,988
1,842
+62.2
ANNUAL
2007
2006
CHG
Profit
($19,787)
($27,257)
+27.4
Per share
(0.40)
(0.81)
+50.6
Sales
10,484
7,043
+48.9
COMMENT: The Redmond developer of miniature display equipment and other light-scanning technologies got most of its 2007 revenue from contract work, but it concentrated its energies on getting its PicoP display engine to market. The goal is to launch the first PicoP-based consumer product by the end of the year.
Northstar Neuroscience
Biomedical equipment
Dec. 31
%
4th QTR
2007
2006
CHG
Profit
($4,857)
($5,272)
+7.9
Per share
(0.19)
(0.21)
+9.5
Revenue
1,150
1,435
-19.9
ANNUAL
2007
2006
CHG
Profit
($23,853)
($27,145)
+12.1
Per share
(0.92)
(1.54)
+40.3
Revenue
5,010
3,287
+52.4
COMMENT: The Seattle company’s quarterly loss narrowed on lower clinical-trial spending. The firm said Thursday it plans to emphasize its clinical program on treating depression through cortical stimulation.